We are doing this study to find out if an experimental drug combination of mirvetuximab (MIRV) plus bevacizumab (BEV) is more effective at managing platinum-sensitive ovarian and fallopian tube cancers in a maintenance setting than bevacizumab on its own.

Recurrent, Platinum-Sensitive Ovarian and Fallopian Tube Cancers

Adults ages 18+ who:

• Are diagnosed with high-grade serous epithelial ovarian or fallopian tube cancer
• Have relapsed after 1 line of platinum-based chemotherapy

For more information about who can be in this study, please contact the study team at 919-684-3780.

If you agree to be in this study, you will get a random assignment (like a coin flip) to 1 of 2 groups:

• One group of participants will get a maintenance study drug regimen of MIRV + BEV
• The other group of participants will get BEV on its own

If you are assigned to the MIRV + BEV group, you will receive an infusion of MIRV followed by an infusion of BEV once every 3 weeks. If you are assigned to the BEV alone group, you will receive an infusion of BEV every 3 weeks.

You can remain enrolled in the study for as long as you and your doctor feel that you are getting a positive benefit from your study regimen.